Evidence from studies in adults show that elevated FGF-21 levels reduce hepatic lipogenesis and improve insulin sensitivity (25, 26) and are negatively correlated with the probability of NAFLD and NASH (14). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.